Emergent and J&J Butt Heads Over Breaches of Contract

June 7, 2022

On Monday, June 6th, Emergent BioSolutions informed Johnson & Johnson that it will owe $420 million if the company terminates their COVID-19 vaccine manufacturing contract. A representative from J&J contested these claims, stating that Emergent breached its end of the contract when it made production errors that resulted in millions of doses to be discarded. J&J further notes that it had been in talks about vaccine production numbers for weeks in advance.

According to Kevin Dunleavy of Fierce Pharma, “J&J is decreasing but not eliminating production of its vaccine. Two months ago, the company said it was not projecting revenue from the shot in 2022. Then in May, the FDA placed restrictions on it because of the threat of rare but serious blood clots. The regulator cited 60 cases of thrombocytopenia, including nine deaths, among the 8 million recipients of the single-dose vaccine.”

To read more, click here.

(Source: Fierce Pharma, June 6th, 2022)

Share This Story!